DeepMed Research

Northwestern University Human Resources

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1851-01-28

Employees: 5K

Market Cap: -

Website: https://www.venturecat.northwestern.edu

Clinical Trials

Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by Surgery

Phase 2

Conditions: Stage IIIB Breast Cancer
Estrogen Receptor Negative
HER2/Neu Negative
Stage III Breast Cancer
Triple-Negative Breast Carcinoma
Progesterone Receptor Negative
Recurrent Breast Carcinoma
Stage IIIA Breast Cancer
Stage IV Breast Cancer
Stage IIIC Breast Cancer

Interventions: Drug: Capecitabine
Other: Laboratory Biomarker Analysis
Biological: Pembrolizumab

First Posted Date: 2017-02-07

Last Posted Date: 2020-07-13

Lead Sponsor: Northwestern University

Target Recruit Count: 30

Registration Number: NCT03044730

Locations: 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
Northwestern Lake Forest Hospital, Lake Forest, Illinois, United States

Barriers to Care and QOL for CCCA Patients

Completed

Conditions: Central Centrifugal Cicatricial Alopecia
Scarring Alopecia
Central Centrifugal Scarring Alopecia

First Posted Date: 2017-02-07

Last Posted Date: 2017-12-13

Lead Sponsor: Northwestern University

Target Recruit Count: 34

Registration Number: NCT03044782

Locations: 🇺🇸
Northwestern University Department of Dermatology, Chicago, Illinois, United States

Mechanical Support Measures of Adjustment and QOL

Completed

Conditions: Heart Failure
Quality of Life
Cardiovascular Diseases

First Posted Date: 2017-02-07

Last Posted Date: 2022-02-16

Lead Sponsor: Northwestern University

Target Recruit Count: 895

Registration Number: NCT03044535

Locations: 🇺🇸
University of California, San Diego, La Jolla, California, United States
🇺🇸
Stanford University Medical Center, Stanford, California, United States
🇺🇸
St. Vincent Hospital, Indianapolis, Indiana, United States

and more 9 locations

The Efficacy and Safety of Secukinumab in Patients With Ichthyoses

Phase 2

Completed

Conditions: Lamellar Ichthyosis
Ichthyosis
Autosomal Recessive Congenital Ichthyosis
Congenital Ichthyosiform Erythroderma
Epidermolytic Ichthyosis
Netherton Syndrome

Interventions: Drug: Placebo
Drug: Secukinumab

First Posted Date: 2017-02-02

Last Posted Date: 2021-08-25

Lead Sponsor: Northwestern University

Target Recruit Count: 20

Registration Number: NCT03041038

Locations: 🇺🇸
Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
🇺🇸
Department of Dermatology Icahn School of Medicine at Mount Sinai, New York, New York, United States

Early Amniotomy Versus Delayed Amniotomy Following Foley Catheter Ripening in Nulliparous Labor Induction

Not Applicable

Completed

Conditions: Labor Induction

Interventions: Procedure: Amniotomy
Device: Foley Catheter
Drug: Misoprostol

First Posted Date: 2017-02-01

Last Posted Date: 2023-04-03

Lead Sponsor: Northwestern University

Target Recruit Count: 69

Registration Number: NCT03039036

Locations: 🇺🇸
Prentice Women's Hospital, Chicago, Illinois, United States

Postpartum Opioid Prescribing Patterns and Patient Utilization

Completed

Conditions: Postpartum
Opioid Use
Post-operative
Cesarean Delivery

Interventions: Other: Survey

First Posted Date: 2017-01-25

Last Posted Date: 2020-02-25

Lead Sponsor: Northwestern University

Target Recruit Count: 494

Registration Number: NCT03030742

Locations: 🇺🇸
Northwestern University, Chicago, Illinois, United States

NU-0129 in Treating Patients With Recurrent Glioblastoma or Gliosarcoma Undergoing Surgery

Early Phase 1

Completed

Conditions: Gliosarcoma
Recurrent Glioblastoma

Interventions: Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Drug: Targeted Molecular Therapy

First Posted Date: 2017-01-13

Last Posted Date: 2022-08-26

Lead Sponsor: Northwestern University

Target Recruit Count: 8

Registration Number: NCT03020017

Locations: 🇺🇸
Northwestern University, Chicago, Illinois, United States

Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer

Phase 4

Active, not recruiting

Conditions: Castration-Resistant Prostatic Cancer
Stage IV Prostate Cancer
Hormone-Refractory Prostate Cancer
Recurrent Prostate Carcinoma
Metastatic Prostate Carcinoma

Interventions: Biological: GnRH agonist/antagonist
Drug: Enzalutamide
Drug: Prednisone
Drug: Abiraterone Acetate

First Posted Date: 2017-01-11

Last Posted Date: 2025-04-27

Lead Sponsor: Northwestern University

Target Recruit Count: 100

Registration Number: NCT03016741

Locations: 🇺🇸
Tulane Cancer Center, New Orleans, Louisiana, United States
🇺🇸
City of Hope Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
Northwestern University, Chicago, Illinois, United States

and more 2 locations

Treating Verbal Memory Deficits Following Chemotherapy for Breast Cancer

Not Applicable

Completed

Conditions: Breast Cancer Treatment
Cognitive Deficits

Interventions: Behavioral: Computerized cognitive treatment

First Posted Date: 2017-01-11

Last Posted Date: 2023-11-07

Lead Sponsor: Northwestern University

Target Recruit Count: 45

Registration Number: NCT03017560

Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects

Phase 2

Active, not recruiting

Conditions: Prostate Cancer Metastatic Castration-Resistant
Metastatic Prostate Carcinoma
Abnormal DNA Repair
Stage IV Prostate Cancer

Interventions: Drug: Olaparib
Drug: Abiraterone Acetate
Drug: Prednisone

First Posted Date: 2017-01-06

Last Posted Date: 2023-08-30

Lead Sponsor: Northwestern University

Target Recruit Count: 70

Registration Number: NCT03012321

Locations: 🇺🇸
Weill Cornell Medical College, New York, New York, United States
🇺🇸
University of Virginia, Charlottesville, Virginia, United States
🇺🇸
Northwestern Medicine, Chicago, Illinois, United States

and more 15 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy